Which has higher earnings & valuation, VERU or MED?

Medifast has higher revenue and earnings than Veru. Medifast is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru N/A N/A -$22.73M -$0.89 N/A Medifast $346.10M 0.38 -$18.67M -$1.83 N/A

Is VERU or MED more profitable?

Veru has a net margin of 0.00% compared to Medifast's net margin of -5.78%. Medifast's return on equity of -4.80% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -54.72% -39.09% Medifast -5.78% -4.80% -3.83%

Does the media refer more to VERU or MED?

In the previous week, Veru had 1 more articles in the media than Medifast. MarketBeat recorded 3 mentions for Veru and 2 mentions for Medifast. Veru's average media sentiment score of 0.43 beat Medifast's score of 0.22 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medifast 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer EL or VERU?

In the previous week, Estee Lauder Companies had 13 more articles in the media than Veru. MarketBeat recorded 16 mentions for Estee Lauder Companies and 3 mentions for Veru. Estee Lauder Companies' average media sentiment score of 1.13 beat Veru's score of 0.43 indicating that Estee Lauder Companies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estee Lauder Companies 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, IPAR or VERU?

Interparfums has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Interparfums $1.49B 2.18 $168.39M $5.27 19.31 Veru N/A N/A -$22.73M -$0.89 N/A

Is IPAR or VERU more profitable?

Interparfums has a net margin of 11.32% compared to Veru's net margin of 0.00%. Interparfums' return on equity of 15.47% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Interparfums 11.32% 15.47% 10.82% Veru N/A -54.72% -39.09%

Does the media prefer IPAR or VERU?

In the previous week, Interparfums had 2 more articles in the media than Veru. MarketBeat recorded 5 mentions for Interparfums and 3 mentions for Veru. Interparfums' average media sentiment score of 0.77 beat Veru's score of 0.43 indicating that Interparfums is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Interparfums 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VERU or PBH?

In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than Veru. MarketBeat recorded 8 mentions for Prestige Consumer Healthcare and 3 mentions for Veru. Veru's average media sentiment score of 0.43 beat Prestige Consumer Healthcare's score of 0.37 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prestige Consumer Healthcare 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, VERU or HLF?

Herbalife has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru N/A N/A -$22.73M -$0.89 N/A Herbalife $5.13B 0.24 $228.30M $2.28 5.31

Is VERU or HLF more profitable?

Herbalife has a net margin of 4.67% compared to Veru's net margin of 0.00%. Herbalife's return on equity of -41.47% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -54.72% -39.09% Herbalife 4.67% -41.47% 8.24%

Veru (VERU) Competitors

$3.00 -0.26 (-7.98%)

Closing price 04:00 PM Eastern

Extended Trading

$3.02 +0.02 (+0.53%)

As of 07:58 PM Eastern

Compare

VERU vs. MED, EL, IPAR, PBH, and HLF

Should you buy Veru stock or one of its competitors? MarketBeat compares Veru with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veru include Medifast (MED), Estee Lauder Companies (EL), Interparfums (IPAR), Prestige Consumer Healthcare (PBH), and Herbalife (HLF). These companies are all part of the "personal products" industry.

How does Veru compare to Medifast?

Veru (NASDAQ:VERU) and Medifast (NYSE:MED) are both small-cap personal products companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Medifast has higher revenue and earnings than Veru. Medifast is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	N/A	N/A	-$22.73M	-$0.89	N/A
Medifast	$346.10M	0.38	-$18.67M	-$1.83	N/A

In the previous week, Veru had 1 more articles in the media than Medifast. MarketBeat recorded 3 mentions for Veru and 2 mentions for Medifast. Veru's average media sentiment score of 0.43 beat Medifast's score of 0.22 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medifast	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veru has a beta of -1.14, indicating that its share price is 214% less volatile than the broader market. Comparatively, Medifast has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Veru presently has a consensus target price of $23.00, indicating a potential upside of 666.67%. Medifast has a consensus target price of $12.00, indicating a potential upside of 1.15%. Given Veru's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veru is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Veru has a net margin of 0.00% compared to Medifast's net margin of -5.78%. Medifast's return on equity of -4.80% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-54.72%	-39.09%
Medifast	-5.78%	-4.80%	-3.83%

47.2% of Veru shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Veru beats Medifast on 9 of the 15 factors compared between the two stocks.

How does Veru compare to Estee Lauder Companies?

Estee Lauder Companies (NYSE:EL) and Veru (NASDAQ:VERU) are both personal products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Estee Lauder Companies has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Veru has a beta of -1.14, meaning that its share price is 214% less volatile than the broader market.

55.2% of Estee Lauder Companies shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 13.1% of Estee Lauder Companies shares are held by company insiders. Comparatively, 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Veru has lower revenue, but higher earnings than Estee Lauder Companies. Estee Lauder Companies is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estee Lauder Companies	$14.33B	2.26	-$1.13B	-$0.70	N/A
Veru	N/A	N/A	-$22.73M	-$0.89	N/A

Veru has a net margin of 0.00% compared to Estee Lauder Companies' net margin of -1.67%. Estee Lauder Companies' return on equity of 20.66% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estee Lauder Companies	-1.67%	20.66%	4.15%
Veru	N/A	-54.72%	-39.09%

Estee Lauder Companies currently has a consensus target price of $100.65, indicating a potential upside of 12.29%. Veru has a consensus target price of $23.00, indicating a potential upside of 666.67%. Given Veru's higher probable upside, analysts plainly believe Veru is more favorable than Estee Lauder Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estee Lauder Companies	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.50
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Estee Lauder Companies had 13 more articles in the media than Veru. MarketBeat recorded 16 mentions for Estee Lauder Companies and 3 mentions for Veru. Estee Lauder Companies' average media sentiment score of 1.13 beat Veru's score of 0.43 indicating that Estee Lauder Companies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estee Lauder Companies	13 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Estee Lauder Companies beats Veru on 10 of the 15 factors compared between the two stocks.

How does Veru compare to Interparfums?

Interparfums (NASDAQ:IPAR) and Veru (NASDAQ:VERU) are both personal products companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Interparfums has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Veru has a beta of -1.14, meaning that its stock price is 214% less volatile than the broader market.

55.6% of Interparfums shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 43.7% of Interparfums shares are owned by company insiders. Comparatively, 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Interparfums has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interparfums	$1.49B	2.18	$168.39M	$5.27	19.31
Veru	N/A	N/A	-$22.73M	-$0.89	N/A

Interparfums has a net margin of 11.32% compared to Veru's net margin of 0.00%. Interparfums' return on equity of 15.47% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Interparfums	11.32%	15.47%	10.82%
Veru	N/A	-54.72%	-39.09%

Interparfums currently has a consensus target price of $106.00, suggesting a potential upside of 4.15%. Veru has a consensus target price of $23.00, suggesting a potential upside of 666.67%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Interparfums.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Interparfums	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Interparfums had 2 more articles in the media than Veru. MarketBeat recorded 5 mentions for Interparfums and 3 mentions for Veru. Interparfums' average media sentiment score of 0.77 beat Veru's score of 0.43 indicating that Interparfums is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Interparfums	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Interparfums beats Veru on 15 of the 16 factors compared between the two stocks.

How does Veru compare to Prestige Consumer Healthcare?

Veru (NASDAQ:VERU) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

47.2% of Veru shares are held by institutional investors. Comparatively, 99.9% of Prestige Consumer Healthcare shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 1.4% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Prestige Consumer Healthcare had 5 more articles in the media than Veru. MarketBeat recorded 8 mentions for Prestige Consumer Healthcare and 3 mentions for Veru. Veru's average media sentiment score of 0.43 beat Prestige Consumer Healthcare's score of 0.37 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prestige Consumer Healthcare	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prestige Consumer Healthcare has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	N/A	N/A	-$22.73M	-$0.89	N/A
Prestige Consumer Healthcare	$1.09B	2.08	$190.30M	$3.91	12.24

Veru presently has a consensus target price of $23.00, suggesting a potential upside of 666.67%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 47.80%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Veru has a beta of -1.14, meaning that its stock price is 214% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Prestige Consumer Healthcare has a net margin of 17.48% compared to Veru's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.54% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-54.72%	-39.09%
Prestige Consumer Healthcare	17.48%	11.54%	6.16%

Summary

Prestige Consumer Healthcare beats Veru on 10 of the 15 factors compared between the two stocks.

How does Veru compare to Herbalife?

Veru (NASDAQ:VERU) and Herbalife (NYSE:HLF) are both small-cap personal products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

47.2% of Veru shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 5.1% of Herbalife shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Herbalife has a net margin of 4.67% compared to Veru's net margin of 0.00%. Herbalife's return on equity of -41.47% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-54.72%	-39.09%
Herbalife	4.67%	-41.47%	8.24%

Veru currently has a consensus price target of $23.00, indicating a potential upside of 666.67%. Herbalife has a consensus price target of $17.80, indicating a potential upside of 46.96%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Herbalife.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Herbalife	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Veru had 3 more articles in the media than Herbalife. MarketBeat recorded 3 mentions for Veru and 0 mentions for Herbalife. Herbalife's average media sentiment score of 1.44 beat Veru's score of 0.43 indicating that Herbalife is being referred to more favorably in the news media.

Company	Overall Sentiment
Veru	Neutral
Herbalife	Positive

Veru has a beta of -1.14, meaning that its share price is 214% less volatile than the broader market. Comparatively, Herbalife has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Herbalife has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Herbalife, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	N/A	N/A	-$22.73M	-$0.89	N/A
Herbalife	$5.13B	0.24	$228.30M	$2.28	5.31

Summary

Herbalife beats Veru on 9 of the 14 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.32M	$8.23B	$6.49B	$11.98B
Dividend Yield	N/A	2.50%	2.67%	5.57%
P/E Ratio	-3.37	15.64	23.85	24.45
Price / Sales	N/A	5.86	572.24	136.74
Price / Cash	N/A	17.17	43.20	54.62
Price / Book	2.40	3.54	10.66	6.80
Net Income	-$22.73M	$225.32M	$3.56B	$337.76M
7 Day Performance	-11.76%	-1.36%	0.05%	2.08%
1 Month Performance	32.16%	1.21%	0.37%	3.16%
1 Year Performance	-54.06%	-3.40%	22.73%	27.78%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	3.0462 of 5 stars	$3.00 -8.0%	$23.00 +666.7%	-51.5%	$52.32M	N/A	N/A	230
MED Medifast	1.4271 of 5 stars	$12.68 +1.2%	$12.00 -5.4%	-10.4%	$139.32M	$385.79M	N/A	870	News Coverage
EL Estee Lauder Companies	4.6559 of 5 stars	$85.76 -3.6%	$101.63 +18.5%	+26.5%	$32.18B	$14.83B	N/A	57,000	Positive News Analyst Forecast
IPAR Interparfums	3.8971 of 5 stars	$92.40 -2.1%	$106.00 +14.7%	-28.9%	$3.02B	$1.49B	17.53	530	Positive News
PBH Prestige Consumer Healthcare	4.5339 of 5 stars	$45.88 -3.5%	$70.75 +54.2%	-44.0%	$2.25B	$1.09B	11.73	540

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors